S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL)
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843752.57052.1e |
| _version_ | 1827332599274536960 |
|---|---|
| author | H. Huang R. Tao Y. Yang H. Cen H. Zhou Y. Guo L Zou J. Cao Y. Huang J. Jin L. Zhang H. Yang X. Xing H. Zhang Y. Liu K. Ding X. Zhu T. Fang H. Dai Q. Qi J. Yang |
| author_facet | H. Huang R. Tao Y. Yang H. Cen H. Zhou Y. Guo L Zou J. Cao Y. Huang J. Jin L. Zhang H. Yang X. Xing H. Zhang Y. Liu K. Ding X. Zhu T. Fang H. Dai Q. Qi J. Yang |
| author_sort | H. Huang |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:02:22Z |
| format | Article |
| id | doaj.art-e345dc7cb26147e190eb9fa18bd5648b |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:02:22Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-e345dc7cb26147e190eb9fa18bd5648b2024-03-03T03:19:20ZengWileyHemaSphere2572-92412022-06-01611611710.1097/01.HS9.0000843752.57052.1e202206003-00116S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL)H. Huang0R. Tao1Y. Yang2H. Cen3H. Zhou4Y. Guo5L Zou6J. Cao7Y. Huang8J. Jin9L. Zhang10H. Yang11X. Xing12H. Zhang13Y. Liu14K. Ding15X. Zhu16T. Fang17H. Dai18Q. Qi19J. Yang201 Sun Yat-sen University Cancer Center, Guangzhou2 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai3 Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, fuzhou4 Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, nanning5 Hunan Cancer Hospital, changsha6 Shanghai East Hospital, Tongji University School of Medicine, Shanghai7 State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, chengdu8 Fudan University Shanghai Cancer Center, Shanghai9 The Affiliated Cancer Hospital of Guiyang Medical University, guiyang10 First Affiliated Hospital, College of Medicine, Zhejiang University, hangzhou11 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan12 Zhejiang Cancer Hospital, hangzhou13 Liaoning Cancer Hospital & Institute, Shenyang14 Tianjin Medical University Cancer Institute & Hospital, tianjin15 Henan Provincial Cancer Hospital, zhengzhou16 Anhui Provincial Cancer Hospital, Hefei17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, China17 CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, Chinahttp://journals.lww.com/10.1097/01.HS9.0000843752.57052.1e |
| spellingShingle | H. Huang R. Tao Y. Yang H. Cen H. Zhou Y. Guo L Zou J. Cao Y. Huang J. Jin L. Zhang H. Yang X. Xing H. Zhang Y. Liu K. Ding X. Zhu T. Fang H. Dai Q. Qi J. Yang S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL) HemaSphere |
| title | S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL) |
| title_full | S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL) |
| title_fullStr | S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL) |
| title_full_unstemmed | S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL) |
| title_short | S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL) |
| title_sort | s215 gemstone 201 pre planned primary analysis of a multicenter single arm phase 2 study of sugemalimab in patients with relapsed or refractory extranodal natural killer t cell lymphoma r r enktl |
| url | http://journals.lww.com/10.1097/01.HS9.0000843752.57052.1e |
| work_keys_str_mv | AT hhuang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT rtao s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT yyang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT hcen s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT hzhou s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT yguo s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT lzou s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT jcao s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT yhuang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT jjin s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT lzhang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT hyang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT xxing s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT hzhang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT yliu s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT kding s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT xzhu s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT tfang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT hdai s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT qqi s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl AT jyang s215gemstone201preplannedprimaryanalysisofamulticentersinglearmphase2studyofsugemalimabinpatientswithrelapsedorrefractoryextranodalnaturalkillertcelllymphomarrenktl |